Treatment with somatostatin analogues (SSAs) or pancreaticoduodenectomy frequently causes malnutrition-inducing pancreatic exocrine insufficiency. This single-centre retrospective cohort study aimed to establish whether pancreatic enzyme replacement therapy (PERT) improves survival or nutritional status in SSA or pancreaticoduodenectomy-treated patients with pancreatic neuroendocrine tumours (pNETs).
SSA and/or pancreaticoduodenectomy-treated patients with pNETs, diagnosed between 2009 and 2019, (n = 77) were retrospectively identified from departmental databases. Data was sourced from clinical records. Overall survival and percentage monthly weight changes were compared between PERT-treated (n = 45) and non-PERT-treated (n = 32) patients.
PERT-treated patients experienced significantly greater median monthly weight gain (+0.01% vs −0.10%, p = 0.038) and 5-year survival (81% vs 51%, p = 0.007). PERT was not, however, independently associated with survival (Hazard ratio 0.47, 95% CI 0.14–1.62, p = 0.232). Considering SSA-treated patients (n = 50) only, PERT-treated patients (n = 24) showed numerically but non-significantly improved monthly weight gain (+0.04% vs −0.18%, p = 0.139) and median survival (55.5, 95% CI 10.2–100.7 vs 42.4, 95% CI 11.7–73.2 months, p = 0.082).
PERT may improve survival and nutrition in SSA and pancreaticoduodenectomy-treated patients with pNETs, however, low patient numbers precluded the reliable mitigation of confounding in this study. A further multi-centre study is required to define the benefits of PERT in this population.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to HPB
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Differences in survival by histologic type of pancreatic cancer.Cancer Epidemiol Prevent Biomarkers. 2005; 14: 1766-1773
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.JAMA Oncol. 2017; 3: 1335-1342
- Pancreatic enzyme therapy for pancreatic exocrine insufficiency.Gastroenterol Hepatol. 2011; 7: 401
- Assessment of exocrine function of pancreas following pancreaticoduodenectomy.Indian j Surg Oncol. 2019; 10: 258-267
- The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors.Pancreas. 2020; 49: 863-881
- New onset of diabetes and pancreatic exocrine insufficiency after pancreaticoduodenectomy for benign and malignant tumors.Ann Surg. 2018; 267: 259-270
- Pancreatic exocrine insufficiency after pancreaticoduodenectomy: current evidence and management.World J Gastrointest Pathophysiol. 2020; 11: 20
- Chronic use of long-acting somatostatin analogues (SSAs) and exocrine pancreatic insufficiency (EPI) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs): an under-recognized adverse effect.Cancer Med J. 2020; 3: 75
- Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs.Pancreatology. 2020; 20: 875-879
- Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.Expet Rev Gastroenterol Hepatol. 2018; 12: 723-731
- Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency.N Engl J Med. 1973; 288: 813-815
- Pancreatic exocrine insufficiency in pancreatic cancer.Nutrients. 2017; 9: 183
- The causes and consequences of cancer-associated malnutrition.Eur J Oncol Nurs. 2005; 9: S51-S63
- Vitamin E in human health and disease.Crit Rev Clin Lab Sci. 2008; 45: 417-450
- Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?.Eur J Cancer. 1998; 34: 503-509
- Inpatient mortality rates are decreased in obese patients with abdominal neuroendocrine tumors.J Surg Res. 2014; 2: 679
- Pancreatic cancer surgery and nutrition management: a review of the current literature.Hepatobiliary Surg Nutr. 2015; 4: 59
- Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasia.Neuroendocrinology. 2017; 104: 11-25
- Insulin dependence and pancreatic enzyme replacement therapy are independent prognostic factors for long-term survival after operation for chronic pancreatitis.Surgery. 2014; 155: 271-279
- Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy.HPB. 2017; 19: 859-867
- Enzyme replacement improves survival among patients with pancreatic cancer: results of a population based study.Pancreatology. 2019; 19: 114-121
- Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.BMC Cancer. 2018; 18: 1-8
- ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site.Neuroendocrinology. 2016; 103: 172-185
- The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.Int J Surg. 2014; 12: 1495-1499
- Prognosis of patients with neuroendocrine tumor: a SEER database analysis.Cancer Manag Res. 2018; 10: 5629
- Surgical resection of primary tumor is associated with prolonged survival in low-grade pancreatic neuroendocrine tumors.Clinics and research in hepatology and gastroenterology. 2021; 45: 101432
- Marital status is an independent prognostic factor for pancreatic neuroendocrine tumors patients: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database.Clin Res Hepatol Gastroenterol. 2017; 41: 476-486
- The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: a prospective cohort study.Pancreas. 2017; 46: 341-346
- Unintentional weight loss is the most important indicator of malnutrition among surgical cancer patients.Neth J Med. 2012; 70: 365-369
- Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region.Gut. 1998; 42: 92-96
- A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.Aliment Pharmacol Ther. 2011; 33: 1152-1161
- Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.Pancreas. 2009; 38: 693-699
- Frequency of appropriate use of pancreatic enzyme replacement therapy and symptomatic response in pancreatic cancer patients.Pancreas. 2019; 48: 780
- Assessment of protein nutritional status.J Nutr. 1990; 120: 1496-1502
Published online: June 15, 2022
Accepted: June 9, 2022
Received: November 8, 2021
☆This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
© 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.